Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa

EE Freeman; RG White; Roel Bakker; KK Orroth; HA Weiss; A Buve; RJ Hayes; JR Glynn

doi:10.1016/j.vaccine.2008.11.074

Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa

EE Freeman, RG White, Roel Bakker, KK Orroth, HA Weiss, A Buve, RJ Hayes, JR Glynn

Public Health

Research output: Contribution to journal › Article › Academic › peer-review

47 Citations (Scopus)

Abstract

Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced Susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. intensified efforts are needed to develop an effective HSV2 vaccine. (C) 2008 Elsevier Ltd. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	940-946
Number of pages	7
Journal	Vaccine
Volume	27
Issue number	6
DOIs	https://doi.org/10.1016/j.vaccine.2008.11.074
Publication status	Published - 2009

Research programs

EMC NIHES-02-65-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2008.11.074

http://hdl.handle.net/1765/24519

Cite this

@article{6f081da068d84b3cae2ab96888500bf4,

title = "Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa",

abstract = "Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced Susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. intensified efforts are needed to develop an effective HSV2 vaccine. (C) 2008 Elsevier Ltd. All rights reserved.",

author = "EE Freeman and RG White and Roel Bakker and KK Orroth and HA Weiss and A Buve and RJ Hayes and JR Glynn",

year = "2009",

doi = "10.1016/j.vaccine.2008.11.074",

language = "Undefined/Unknown",

volume = "27",

pages = "940--946",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa

AU - Freeman, EE

AU - White, RG

AU - Bakker, Roel

AU - Orroth, KK

AU - Weiss, HA

AU - Buve, A

AU - Hayes, RJ

AU - Glynn, JR

PY - 2009

Y1 - 2009

N2 - Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced Susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. intensified efforts are needed to develop an effective HSV2 vaccine. (C) 2008 Elsevier Ltd. All rights reserved.

AB - Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced Susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. intensified efforts are needed to develop an effective HSV2 vaccine. (C) 2008 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.vaccine.2008.11.074

DO - 10.1016/j.vaccine.2008.11.074

M3 - Article

C2 - 19071187

SN - 0264-410X

VL - 27

SP - 940

EP - 946

JO - Vaccine

JF - Vaccine

IS - 6

ER -